Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil

International Journal of Pharmaceutics

Volumn 506, Issue 1-2, 2016, Pages 129-137

  Fukuta, Tatsuya ^a,b   Asai, Tomohiro ^a   Sato, Akihiko ^a   Namba, Mio ^a   Yanagida, Yosuke ^a   Kikuchi, Takashi ^a   Koide, Hiroyuki ^a   Shimizu, Kosuke ^a   Oku, Naoto ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

Blood brain barrier; Cerebral ischemia reperfusion injury; Fasudil; Ischemic stroke; Liposomes; Middle cerebral artery occlusion

Indexed keywords

FASUDIL; LIPOSOME; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; BRAIN NERVE CELL; CELL DAMAGE; CELL INFILTRATION; CELL INVASION; CELL PROTECTION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG RELEASE; DRUG RETENTION; FLUORESCENCE; LIPOSOMAL DELIVERY; MACROPHAGE; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NEUTROPHIL; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; INFARCTION, MIDDLE CEREBRAL ARTERY; INTRAVENOUS DRUG ADMINISTRATION; PROCEDURES; STROKE; WISTAR RAT;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADMINISTRATION, INTRAVENOUS; ANIMALS; BRAIN; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; INFARCTION, MIDDLE CEREBRAL ARTERY; LIPOSOMES; MALE; NEUROPROTECTION; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; REPERFUSION INJURY; STROKE;

EID: 84964669460     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2016.04.046     Document Type: Article

References (35)

1. T.M. Allen, C.B. Hansen, and D.E.L. de Menenez Pharmacokinetics of long-circulating liposomes Adv. Drug Deliv. Rev. 16 1995 267 284
2. L.C. Davies, S.J. Jenkins, J.E. Allen, and P.R. Taylor Tissue-resident macrophages Nat. Immunol. 14 2013 986 995
3. T. Fukuta, T. Ishii, T. Asai, G. Nakamura, Y. Takeuchi, A. Sato, Y. Agato, K. Shimizu, S. Akai, D. Fukumoto, N. Harada, H. Tsukada, A.T. Kawaguchi, and N. Oku Real-time trafficking of PEGylated liposomes in the rodent focal brain ischemia analyzed by positron emission tomography Artif. Organs 38 2014 662 666
4. T. Fukuta, T. Ishii, T. Asai, A. Sato, T. Kikuchi, K. Shimizu, T. Minamino, and N. Oku Treatment of stroke with liposomal neuroprotective agents under cerebral ischemia conditions Eur. J. Pharm. Biopharm. 97 2015 1 7
5. M.D. Ginsberg Neuroprotection for ischemic stroke: past, present and future Neuropharmacology 55 2008 363 389
6. M.D. Ginsberg Current status of neuroprotection for cerebral ischemia: synoptic overview Stroke 40 2009 S111 S114
7. V. Gupta, N. Gupta, I.H. Shaik, R. Mehvar, I.F. McMurtry, M. Oka, E. Nozik-Grayck, M. Komatsu, and F. Ahsan Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension J. Control. Release 167 2013 189 199
8. H. Harashima, Y. Ohnishi, and H. Kiwada In vivo evaluation of the effect of the size and opsonization on the hepatic extraction of liposomes in rats: an application of Oldendorf method Biopharm. Drug Dispos. 13 1992 549 553
9. H. Harashima, K. Sakata, K. Funato, and H. Kiwada Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes Pharm. Res. 11 1994 402 406
10. A.J. Hunter, J. Hatcher, D. Virley, P. Nelson, E. Irving, S.J. Hadingham, and A.A. Parsons Functional assessments in mice and rats after focal stroke Neuropharmacology 39 2000 806 816
11. C. Iadecola, and J. Anrather Stroke research at a crossroad: asking the brain for directions Nat. Neurosci. 14 2011 1363 1368
12. T. Ishida, Y. Takanashi, H. Doi, I. Yamamoto, and H. Kiwada Encapsulation of an antivasospastic drug, fasudil, into liposomes, and in vitro stability of the fasudil-loaded liposomes Int. J. Pharm. 232 2002 59 67
13. T. Ishida Development of drug delivery system for intrathecal administration and its therapeutic effect on cerebral vasospasm and ischemia Yakugaku Zasshi 124 2004 541 547
14. M. Ishiguro, K. Kawasaki, Y. Suzuki, F. Ishizuka, K. Mishiro, Y. Egashira, I. Ikegaki, K. Tsuruma, M. Shimazawa, S. Yoshimura, T. Iwama, and H. Hara A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator Neuroscience 220 2012 302 312
15. T. Ishii, T. Asai, T. Fukuta, D. Oyama, N. Yasuda, Y. Agato, K. Shimizu, T. Minamino, and N. Oku A single injection of liposomal asialo-erythropoietin improves motor function deficit caused by cerebral ischemia/reperfusion Int. J. Pharm. 439 2012 269 274
16. T. Ishii, T. Asai, D. Oyama, T. Fukuta, N. Yasuda, K. Shimizu, T. Minamino, and N. Oku Amelioration of cerebral ischemia-reperfusion injury based on liposomal drug delivery system with asialo-erythropoietin J. Control. Release 160 2012 81 87
17. T. Ishii, T. Asai, D. Oyama, Y. Agato, N. Yasuda, T. Fukuta, K. Shimizu, T. Minamino, and N. Oku Treatment of cerebral ischemia-reperfusion injury with PEGylated liposomes encapsulating FK506 FASEB J. 27 2013 1362 1370
18. T. Ishii, T. Fukuta, Y. Agato, D. Oyama, N. Yasuda, K. Shimizu, A.T. Kawaguchi, T. Asai, and N. Oku Nanoparticles accumulate in ischemic core and penumbra region even when cerebral perfusion is reduced Biochem. Biophys. Res. Commun. 430 2013 1201 1205
19. S.E. Lakhan, A. Kirchgessner, D. Tepper, and A. Leonard Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke Front. Neurol. 4 2013 32
20. L.L. Latour, D.W. Kang, M.A. Ezzeddine, J.A. Chalela, and S. Warach Early blood-brain barrier disruption in human focal brain ischemia Ann. Neurol. 56 2004 468 477
21. M.A. Moskowitz, E.H. Lo, and C. Iadecola The science of stroke: mechanisms in search of treatments Neuron 67 2010 181 198
22. B.K. Mueller, H. Mack, and N. Teusch Rho kinase, a promising drug target for neurological disorders Nat. Rev. Drug Discov. 4 2005 387 398
23. H. Nagasawa, and K. Kogure Correlation between cerebral blood flow and histologic changes in a new rat model of middle cerebral artery occlusion Stroke 20 1989 1037 1043
24. K.S. Panickar, and M.D. Norenberg Astrocytes in cerebral ischemic injury: morphological and general consideration Glia 50 2005 287 298
25. T. Rhim, D.Y. Lee, and M. Lee Drug delivery systems for the treatment of ischemic stroke Pharm. Res. 30 2013 2429 2444
26. Y. Rikitake, H.H. Kim, Z. Huang, M. Seto, K. Yano, T. Asano, M.A. Moskowitz, and J.K. Liao Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection Stroke 36 2005 2251 2257
27. S. Satoh, Y. Toshima, A. Hitomi, I. Ikegaki, M. Seto, and T. Asano Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model Brain Res. 1193 2008 102 108
28. S. Satoh, A. Hitomi, I. Ikegaki, K. Kawasaki, O. Nakazono, M. Iwasaki, M. Mohri, and T. Asano Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage Brain Res. Bull. 81 2010 191 195
29. K. Satoh, Y. Fukumoto, and H. Shimokawa Rho-kinase: important new therapeutic target in cardiovascular diseases Am. J. Physiol. Heart Circ. Physiol. 301 2011 H287 296
30. M. Shibuya, S. Hirai, M. Seto, S. Satoh, and E. Ohtomo Fasudil Ischemic Stroke Study Group. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial Neurol. Sci. 238 2005 31 39
31. T. Shichita, T. Ago, M. Kamouchi, T. Kitazono, A. Yoshimura, and H. Ooboshi Novel therapeutic strategies targeting innate immune responses and early inflammation after stroke J. Neurochem. 123 Suppl. 2 2012 29 38
32. T. Shichita, E. Hasegawa, A. Kimura, R. Morita, R. Sakaguchi, I. Takada, T. Sekiya, H. Ooboshi, T. Kitazono, T. Yanagawa, T. Ishii, H. Takahashi, S. Mori, M. Nishibori, K. Kuroda, S. Akira, K. Miyake, and A. Yoshimura Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain Nat. Med. 18 2012 911 917
33. L. Silverman, and Y. Barenholz In vitro experiments showing enhanced release of doxorubicin from Doxil(R) in the presence of ammonia may explain drug release at tumor site Nanomedicine 11 2015 1841 1850
34. A.M. Stowe, T.L. Adair-Kirk, E.R. Gonzales, R.S. Perez, A.R. Shah, T.S. Park, and J.M. Gidday Neutrophil elastase and neurovascular injury following focal stroke and reperfusion Neurobiol. Dis. 35 2009 82 90
35. V.P. Torchilin Multifunctional nanocarriers Adv. Drug Deliv. Rev. 64 2012 302 315